Intervening in the neuropsychiatric features of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 6, 2007, Pages 699-710

  Weintraub, Daniel ^a,b   Stern, Matthew B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; Dementia; Depression; Parkinson's disease; Psychiatric; Psychosis

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ARIPIPRAZOLE; ATOMOXETINE; BENZODIAZEPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DEXTROMETHORPHAN; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHYLPHENIDATE; MODAFINIL; PRAMIPEXOLE; QUETIAPINE; QUINIDINE; RASAGILINE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALZHEIMER DISEASE; ANHEDONIA; ANXIETY DISORDER; APATHY; AUTONOMIC DYSFUNCTION; BODY TEMPERATURE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COORDINATION DISORDER; DECREASED APPETITE; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERREFLEXIA; HYPOTHERMIA; IMPULSE CONTROL DISORDER; INSOMNIA; LANGUAGE DISABILITY; LEWY BODY; MENTAL INSTABILITY; PARKINSON DISEASE; PERSONALITY DISORDER; PSYCHOMOTOR DISORDER; PSYCHOSIS; PSYCHOTHERAPY; RESTLESSNESS; REVIEW; RIGIDITY; SIDE EFFECT; SLEEP DISORDER; SPEECH DISORDER; SUICIDAL IDEATION; TREMOR; WAKEFULNESS;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DRUG COMBINATIONS; HUMANS; MENTAL DISORDERS; NOOTROPIC AGENTS; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 34250306015     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.6.699     Document Type: Review

References (107)

1. Tandberg E, Larsen JP, Aarsland D et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch. Neurol. 53, 175-179 (1996).
2. Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions in major depression and Parkinson disease. Arch. Neurol. 54, 982-986 (1997).
3. Marsh L, Williams JR, Rocco M et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63, 293-300 (2004).
4. Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism Relat. Disord. 12, 427-431 (2006).
5. Rojo A, Aguilar M, Garolera MT et al. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat. Disord. 10, 23-28 (2003).
6. Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov. Disord. 21, 148-158 (2006).
7. Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int. J. Geriatr. Psychiatry 21, 252-258 (2006). • In this direct comparison, depressed Parkinson's disease (PD) patients reported less sadness, less anhedonia and fewer feelings of guilt, but more concentration problems than depressed non-PD patients.
8. Shulman LM, Taback RL, Rabinstein AA et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8, 193-197 (2002).
9. Weintraub D, Moberg PJ, Duda JE et al. Recognition and treatment of depression in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 178-183 (2003).
10. Ehmann TS, Beninger RJ, Gawel MJ et al. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol. 2, 3-9 (1989).
11. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol. Scand. 113, 211-220 (2006). •• Showed consistently heightened rates of depression and anxiety disorders before onset of PD, suggesting that they have neurobiological underpinnings.
12. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128, 1314-1322 (2005).
13. Burn DJ, Tiangyou W, Allcock LM, Davison J, Chinnery PF. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism Relat. Disord. 12, 139-141 (2006).
14. Leentjens AF, Scholtissen B, Vreeling FW, Verhey FR. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 31, 1009-1015 (2006).
15. Richard IH, Kurlan R; Parkinson Study Group. A survey of antidepressant use in Parkinson's disease. Neurology 49, 1168-1170 (1997).
16. Chung TH, Deane KHO, Ghazi-Noori S et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat. Disord. 10, 59-65 (2003).
17. Leentjens AF, Vreeling FW, Luijckx GJ et al. SSRIs in the treatment of depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 18, 552-554 (2003).
18. Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov. Disord. 20, 1161-1169 (2005). • This meta-analysis found no evidence to support the efficacy of antidepressants in PD, and preliminary evidence that antidepressants are less effective in this population than in elderly depressed patients without PD.
19. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur. J. Neurol. 10, 399-406 (2003).
20. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J. Neurol. 253, 601-607 (2006).
21. Allain H, Cougnard J, Neukirch H-C et al. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol. Scand. 84(Suppl. 136), 73-78 (1991).
22. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a doubleblind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry 159, 1869-1875 (2002).
23. Moellentine C, Rummans T, Ahlskog JE et al. Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10, 187-193 (1998).
24. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am. J. Geriatr. Psychiatry 14, 169-175 (2006).
25. McDonald WM, Holtzheimer PE, Haber M, Vitek JL, McWhorter K, Delong M. Validity of the 30-item geriatric depression scale in patients with Parkinson's disease. Mov. Disord. 21, 1618-1622 (2006).
26. Alexopoulos GS, Katz IR, Reynolds CF III, Carpenter D, Docherty JP; Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad. Med. 1-86 (2001).
27. Fénelon G, Mahieux F, Huon R et al. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 123, 733-745 (2000).
28. Aarsland D, Larsen JP, Cummings JL et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. Arch. Neurol. 56, 595-601 (1999).
29. Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov. Disord. 20, 1439-1448 (2005).
30. Feldman B, Chapman J, Korczyn AD. Apolipoprotein ε4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol. Scand. 113, 14-17 (2006).
31. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63, 293-300 (2004).
32. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528-536 (2001).
33. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708-1715 (2005).
34. Matsui H, Nishinaka K, Oda M et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov. Disord. 21, 2140-2144 (2006).
35. Matsui H, Nishinaka K, Oda M et al. Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. Mov. Disord. 21, 2165-2169 (2006).
36. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of druginduced psychosis in Parkinson's disease. Mov. Disord. 15, 201-211 (2000).
37. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20, 958-963 (2005). • Placebo-controlled study in which quetiapine failed to demonstrate efficacy, calling into question its use as the first-line antipsychotic in PD.
38. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov. Disord. 22, 313-318 (2007).
39. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763 (1999).
40. Friedman JH, Barman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov. Disord. 21, 2078-2081 (2006).
41. Fabbrini G, Barbanti P, Aurilia C et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. 23, 41-43 (2002).
42. Reading PJ, Luce AK, McKeith IJ. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. 16, 1171-1195 (2001).
43. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr. Med. Res. Opin. 18, 258-264 (2002).
44. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin. Neuropharmacol. 27, 90-92 (2004).
45. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 311-313 (2007).
46. Friedberg G, Zoldan J, Weizman A et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin. Neuropharmacol. 21, 280-284 (1998).
47. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20, 1255-1263 (2005).
48. Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387-392 (2003). •• In this large, long-term, community-based study, the 8-year cumulative prevalence of dementia in PD was nearly 80%, a much higher rate than has been found in cross-sectional studies.
49. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239-1245 (2005).
50. Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 61, 1906-1911 (2004).
51. Pillon B, Deweer B, Agid Y et al. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Neurol. 50, 374-379 (1993).
52. Turner MA, Moran NF, Kopelman MD. Subcortical dementia. Br. J. Psychiatry 180, 148-151 (2002).
53. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn. Behav. Neurol. 17, 195-200 (2004).
54. Hurtig HI, Trojanowski JQ, Galvin J et al. α-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916-1921 (2000).
55. Kovari E, Gold G, Herrmann FR et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol. (Berl.) 106, 83-88 (2003).
56. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404-1410 (2005).
57. Burn DJ, O'Brien JT. Use of functional imaging in parkinsonism and dementia. Mov. Disord. 18(Suppl. 6), S88-S95 (2003).
58. Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci. Biobehav. Rev. 26, 785-793 (2002).
59. Hilker R, Thomas AV, Klein JC et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65, 1716-1722 (2005).
60. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004). •• Only large-scale placebo-controlled trial of a cholinesterase inhibitor for PD dementia. The results were statistically significant in favor of rivastigmine, but only 20% of rivastigmine-treated subjects experienced clinically meaningful improvement.
61. Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21(4), 456-461 (2006).
62. Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1-8 (2004).
63. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76, 934-939 (2005).
64. Aarsland D, Mosimann UP, McKeith IJ. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol. 17, 164-171 (2004).
65. Minett TSC, Thomas A, Wilkinson LM et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18, 988-993 (2003).
66. Nasreddine ZS, Phillips NA, Bédirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695-699 (2005).
67. Marinus J, Visser M, Verwey NA et al. Assessment of cognition in Parkinson's disease. Neurology 61, 1222-1228 (2003).
68. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad. Med. J. 77, 89-93 (2001).
69. Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 35-41 (2001).
70. Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson's Disease: a case-control study. Mov. Disord. 15, 669-677 (2000).
71. Isella V, Melzi P, Grimaldi M et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov. Disord. 17, 366-371 (2002).
72. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology 67, 33-38 (2006).
73. Robert PH, Berr C, Volteau M et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clin. Neurol. Neurosurg. 108, 733-736 (2006).
74. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 38, 143-162 (1991).
75. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 4, 134-139 (1992).
76. Cummings JL, Arciniegas DB, Brooks BR et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 11(6 Suppl. 6), 1-7 (2006).
77. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61, 422-423 (2003).
78. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov. Disord. 21, 524-529 (2006).
79. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat. Disord. 11, 381-386 (2005).
80. Evans AH, Katzenschlager R, Paviour D et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov. Disord. 19, 397-405 (2004).
81. Weintraub D, Siderowf AD, Potenza MN et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol. 63, 969-973 (2006). •• The primary findings were an association between a current impulse control disorders (ICD) and both dopamine (DA) agonist use and a history of ICD behaviors before PD onset, as well as a suggestion of a dosage effect for DA agonists and no difference in ICD rates among commonly used DA agonists.
82. Voon V, Hassan K, Zurowski M et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66, 1750-1752 (2006).
83. Potenza MN, Leung H-C, Blumberg HP et al. An fMRI Stroop task study in ventromedial prefrontal cortical function in pathological gamblers. Am. J. Psychiatry 160, 1990-1994 (2003).
84. Ardouin C, Voon V, Worbe Y et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov. Disord. 21, 1941-1946 (2006).
85. Friedman JH, Chou KL. Sleep and fatigue in Parkinson's disease. Parkinsonism Relat. Disord. 10, S27-S35 (2004). • Excellent review of disorders of sleep and wakefulness, which are the most common nonmotor complications in PD.
86. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 51, 526-529 (1998).
87. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46, 388-393 (1996).
88. Eisensehr I, Linke R, Noachtar S et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. Comparison with Parkinson's disease and controls. Brain 123, 1155-1160 (2000).
89. Phillips B. Movement disorders: a sleep specialist's perspective. Neurology 62(Suppl. 2), S9-S16 (2004).
90. Chaudhuri A, Behan PO. Fatigue and basal ganglia. J. Neurol. Sci. 179, 34-42 (2000).
91. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287, 455-463 (2002).
92. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67, 853-858 (2006).
93. Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65, 1442-1446 (2005).
94. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry 76, 1636-1639 (2005).
95. Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 43, 505-508 (1993).
96. Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov. Disord. 21, 1066-1072 (2006). • Authors summarize years of literature and highlight the limitations of trying to characterize a parkinsonian personality.
97. Kaasinen V, Nurmi E, Bergman J et al. Personality traits and brain dopaminergic function in Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 13272-13277 (2001).
98. Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov. Disord. 17, S63-S68 (2002).
99. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 13, 1925-1934 (2003).
100. Schüpbach WMM, Chastan N, Welter ML et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry 76, 1640-1644 (2005).
101. Voon V, Kubu C, Krack P, Houeto JL, Troster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov. Disord. 21(Suppl. 14), S305-S327 (2006). •• Excellent recent review of a complex topic, the psychiatric and cognitive changes associated with deep brain stimulation, which is increasingly being used to treat PD.
102. Herzog J, Volkmann J, Krack P et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov. Disord. 18, 1332-1337 (2003).
103. Smeding HM, Speelman JD, Koning-Haanstra M et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 66, 1830-1836 (2006).
104. Houeto JL, Mesnage V, Mallet L et al. Behavioral disorders, Parkinson's disease and subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry 72, 701-707 (2002).
105. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol. 5, 578-588 (2006).
106. Berney A, Vingerhoets F, Perrin A et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 59, 1427-1429 (2002).
107. Miyasaki JM, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 996-1002 (2006).